Huntingtons Disease Treatment Market: By Drug Class (Anticonvulsants, Antidepressants, Antidopaminergics, Antipsychotics, Others), By Route of Administration (Oral, Parenteral), By Distribution Channel (Hospitals pharmacies, Retail pharmacies, Online pharmacies) and Geography

Huntingtons Disease Treatment Market size was estimated at USD 330.3 million in 2023 and is poised to grow at a CAGR of 23.20% from 2024-2030. Huntingtons Disease Treatment Market report gives a comprehensive outlook on across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report on global Huntingtons Disease Treatment market gives historical, current, and future market sizes (US$ Mn) of drug class, route of administration, distribution channel and geographic regions. This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities).

Key stakeholders of the report include suppliers, manufacturers, marketers, policymakers engaged in manufacturing and supply of global market. Huntingtons disease is an inherited disorder caused due to degeneration of the nerve cells in the brain. Huntingtons disease signs and symptoms appear in people with 30 to 40 years of age and sometimes disease causes in below 20 years of age group. Most common symptoms of Huntington's disease include difficulties in learning, lack of flexibility, muscle problems, abnormalities in speech, and lack of impulse control. Moreover, depression is the most common psychiatric disorder occurs with Huntington's disease and caused due to damage of brain cells and changes in brain function. There is no permanent treatment for Huntington's disease however, medications are available to manage the symptoms of Huntington's disease.

Huntingtons Disease Treatment Market Key Developments

• In April 2017, Teva Pharmaceuticals Industries Ltd. received U.S. FDA approval for Austedo tablets used in the treatment of Huntington's disease treatment. In September 2016, Voyager Therapeutics, Inc. collaborated with CHDI Foundation, Inc. (CHDI) foundation to develop novel gene therapy for the treatment of Huntington's disease.